|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial显示文摘瞄准:在幸存上调查长期的白朊管理的效果,腹水的复发和另外的复杂并发症的发作。方法:为第一发作的腹水招收的 100 个连续病人被使随机化加人的白朊收到利尿剂第一年和 25 g 里的 25 g/wk 每二 wk 此后(组 1 ) 或利尿剂独自一个(组 2 ) 。没有肝移植,主要端点是幸存。第二等的端点是腹水的复发和另外的复杂并发症的出现。结果:中部的后续是 84 (2-120 ) 瞬间。对待白朊的病人有显著地更大的累积幸存率(Breslow test=7.05, P=0.0078 ) 并且腹水复发的更低的概率(51% 对 94% , P<0.0001 ) 。长期的白朊注入导致了 16 瞬间的幸存的吝啬的增加。结论:在第一发作的腹水以后的长期的白朊管理显著地改进病人的幸存并且减少腹水复发的风险。 | Roberto Giulio Romanelli Giorgio La Villa Giuseppe Barletta Francesco Vizzutti Fabio Lanini Umberto Arena Vieri Boddi Roberto Tarquini Pietro Pantaleo Paolo Gentilini Giacomo Laffi | 2006 | World Journal of Gastroenterology2006，12，9： | 22 |
| 2 | Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis显示文摘 | Andrea Lisotti Francesco Azzaroli Federica Buonfiglioli Marco Montagnani Paolo Cecinato Laura Turco Claudio Calvanese Patrizia Simoni Massimo Guardigli Rosario Arena Alessandro Cucchetti Antonio Colecchia Davide Festi Rita Golfieri Giuseppe Mazzella | 2014 | Hepatology2014，，2： | 2 |
| 3 | Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: a case report and systematic review of literature显示文摘Mild to moderate autoimmune thrombocytopenia(AITP) is a common finding in patients receiving interferonbased antiviral treatment, due to bone marrow suppression. Here we report the case of a patient with chronic genotype 1b hepatitis C virus(HCV) infection treated with pegylated-interferon alpha-2a, ribavirin and telaprevir for 24 wk; the patient developed severe AITP three weeks after treatment withdrawal. We performed a systematic literature search in order to review all published cases of AITP related to HCV antiviral treatment. To our knowledge, this is the second case of AITP observed after antiviral treatment withdrawal. In most published cases AITP occurred during treatment; in fact, among 24 cases of AITP related to interferonbased antiviral treatment, only one occurred after discontinuation. Early diagnosis of AITP is a key factor in order to achieve an early interferon discontinuation; in the era of new direct antiviral agents those patients have to be considered for interferon-free treatment regimens. Prompt prescription of immuno-suppressant treatment(i.e., corticosteroids, immunoglobulin infusion and even rituximab for unresponsive cases) leads to favourable prognosis in most of cases. Physicians using interferonbased treatments should be aware that AITP can occur both during and after treatment, specially in the new era of interferon-free antiviral treatment. Finally, in the case of suspected AITP, presence of anti-platelet antibodies should be checked not only during treatment but alsoafter discontinuation. | Rosario Arena Paolo Cecinato Andrea Lisotti Federica Buonfiglioli Claudio Calvanese Giuseppe Grande Marco Montagnani Francesco Azzaroli Giuseppe Mazzella | 2015 | World Journal of Hepatology2015，7，12： | 2 |
| 4 | A characterization study of the surface acidity of solid catalysts by temperature programmed methods 显示文摘 | Francesco Arena Roberto Dario Adolofo Parmaliana | 1998 | Applied Catalysis1998，17，： | 1 |
| 5 | Assessment of the Genetic Effects of Polymorphisms in the Osteoprotegerin Gene, TNFRSF11B, on Serum Osteoprotegerin Levels and Carotid Plaque Vulnerability显示文摘 | Giuseppe Straface Federico Biscetti Dario Pitocco Giovanni Bertoletti Maria Misuraca Claudio Vincenzoni Francesco Snider Vincenzo Arena Egidio Stigliano Flavia Angelini Luigi Iuliano Stefania Boccia Chiara de Waure Francesco Giacchi Giovanni Ghirlanda And | 2011 | Stroke2011，，： | 1 |
| 6 | Palladium catalysts supported on digomeric aramides in the liquid-phase hydrogenation of phenylacetylene显示文摘 | Francesco Arena Giampletro Cum Raffade Gallo | 1996 | Journal of Molecular Catalysis1996，110，： | 1 |
| 7 | A characterization study of the surface acidity of solid catalysts by temperature programmed methods显示文摘 | Roberto Dario Adolofo Parmaliana | 1998 | Appl Catal: A1998，170，1： | 1 |
| 8 | 显示文摘 | ADOLFO PARMALIANA FRANCESCO ARENA | 1997 | Journal of Catalysis1997，167，1： | 1 |
| 9 | 显示文摘 | FRANCESCO ARENA NICOLA GIORDANO ADOLFO PARMALIANA | 1997 | Journal of Catalysis1997，167，1： | 1 |
| 10 | Could inflammatory markers help diagnose nonalcoholic steatohepatitis?显示文摘 | Giovanni Tarantino Paolo Conca Fabrizio Pasanisi Manuela Ariello Maria Mastrolia Adriano Arena Marianna Tarantino Francesco Scopacasa Raffaela Vecchione | 2009 | European Journal of Gastroenterology & Hepatology2009，，5： | 1 |
| 11 | Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases显示文摘AIM:To assess clinical and endoscopic response to propionyl-L-carnitine hydrochloride(PLC) in colonic inflammatory bowel disease.METHODS:Patients suffering from mild to moderate ulcerative colitis(UC) or Crohn's disease(CD) colitis,with disease activity index(DAI) between 3 and 10 and under stable therapy with oral aminosalicylates,mercaptopurine or azathioprine,for at least 8 wk prior to baseline assessments,were considered suitable for enrollment.Fourteen patients were enrolled to assume PLC 2 g/d(two active tablets twice daily) orally.Clinical-endoscopic and histological activity were assessed by DAI and histological index(HI),respectively,following a colonoscopy performed immediately before and after 4 wk treatment.Clinical response was defined as a lowering of at least 3 points in DAI and clinical remission as a DAI score ≤ 2.Histological response was defined as an improvement of HI of at least 1 point.We used median values for the analysis.Differences pre-and post-treatment were analyzed by Wilcoxon signed rank test.RESULTS:All patients enrolled completed the study.One patient,despite medical advice,took deflazacort 5 d before follow-up colonoscopy examination.No side effects were reported by patients during the trial.After treatment,71%(SE 12%) of patients achieved clinical response,while 64%(SE 13%) obtained remission.Separating UC from CD patients,we observed a clinical response in 60%(SE 16%) and 100%,respectively.Furthermore 60%(SE 16%) of UC patients and 75%(SE 25%) of CD patients were in clinical remission after therapy.The median DAI was 7 [interquartile range(IQR):4-8] before treatment and decreased to 2(IQR:1-3)(P < 0.01) after treatment.Only patients with UC showed a significant reduction of DAI,from a median 6.5(IQR:4-9) before treatment to 2(IQR:1-3) after treatment(P < 0.01).Conversely,in CD patients,although displaying a clear reduction of DAI from 7(IQR:5.5-7.5) before therapy to 1.5(IQR:0.5-2.5) after therapy,differences observed were not significant(P = 0.06).Seventy-nine percent(SE 11%) of patients showed improvement of HI of at least 1 point,while only one CD and two UC patients showed HI stability;none showed HI worsening.Median HI decreased from 1(IQR:1-2),to 0.5(IQR:0-1) at the endoscopic control in the whole population(P < 0.01),while it changed from 1(IQR:1-2) to 0.5(IQR:0-1) in UC patients(P < 0.01) and from 1.5(IQR:1-2) to 0.5(IQR:0-1) in CD patients(P = not significant).The two sample tests of proportions showed no significant differences in clinical and histological response or in clinical remission between UC and CD patients.No side effects were reported during treatment or at 4 wk follow-up visit.CONCLUSION:PLC improves endoscopic and histological activity of mild to moderate UC.Further studies are required to evaluate PLC efficacy in colonic CD patients. | Giuseppe Merra Giovanni Gasbarrini Lucrezia Laterza Marco Pizzoferrato Andrea Poscia Franco Scaldaferri Vincenzo Arena Francesca Fiore Achille Cittadini Alessandro Sgambato Francesco Franceschi Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 12 | Synthesis, characterization and activity pattern of Cu-ZnO/ZrO2 catalysts in the hydrogenation of carbon dioxide to methanol显示文摘 | Francesco Arena Katia Barbera Giuseppe Italiano | 2007 | Journal of Catalysis2007，249，2： | 1 |
| 13 | Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis显示文摘 | Annalisa Berzigotti Susana Seijo Umberto Arena Juan G. Abraldes Francesco Vizzutti Juan Carlos García–Pagán Massimo Pinzani Jaime Bosch | 2013 | Gastroenterology2013，，1： | 1 |
| 14 | Synthesis, characterization and activity pattern of Cu-ZnO/ZrO2 catalysts in the hydrogenation of carbon dioxide tomethanol显示文摘 | Francesco Arena Katia Barbera Giuseppe Italiano | 2007 | Journal of Catalysis2007，249，2： | 1 |
| 15 | Role of the ceria promoter and carrier on the functionality of Cu-based catalysts in the CO 2 -to-methanol hydrogenation reaction显示文摘 | Giuseppe Bonura Francesco Arena Giovanni Mezzatesta Catia Cannilla Lorenzo Spadaro Francesco Frusteri | 2011 | Catalysis Today2011，，1： | 1 |
| 16 | Could inflammatory markers help diagnose nonalcoholic steatohepatitis?显示文摘 | Giovanni Tarantino Paolo Conca Fabrizio Pasanisi Manuela Ariello Maria Mastrolia Adriano Arena Marianna Tarantino Francesco Scopacasa Raffaela Vecchione | 2009 | European Journal of Gastroenterology & Hepatology2009，，5： | 1 |
| 17 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib显示文摘AIM:To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma(HCC)in patients with established cirrhosis.METHODS:From October 2009 to July 2012 patients with an established diagnosis of cirrhosis and HCC treated with sorafenib were consecutively enrolled.According to the Barcelona Clinic Liver Cancer(BCLC)classification,patients were in the advanced stage(BCLC-C)or in the intermediate stage(BCLC-B)but unfit or unresponsive to other therapeutic strategies.Treatment was evaluated performing a 4-phase computed tomography or magnetic resonance imaging scan every 2-3 mo,and analyzed according to the modified Response Evaluation Criteria in Solid Tumors.Sorafenib was administered at 800 mg/d,until radiological progression or occurrence of unacceptable adverse events(AEs).Univariate and multivariate analyses identified predictors of 16-wk clinical benefit and overall survival.RESULTS:Forty-four patients were enrolled,15 had intermediate HCC and 14 a Child-Pugh score of B7.AEs caused treatment interruption in 19 patients(43%),and median treatment duration was shorter in this subset(5 wk vs 19 wk,P<0.001)and in the BCLC-C subgroup(13 wk vs 40 wk,P=0.015).No significant differences in the reason for treatment interruption or in treatment duration were found comparing patients in Child-Pugh class A vs B or in patients older or younger than 70 years.After 16 wk of treatment,18 patients(41%)had stable disease or partial response.Patients with viral infection or BCLC-C were at higher risk of disease progression.ECOG,extrahepatic spread,macrovascular invasion,alpha-fetoprotein or alkaline phosphatase levels at admission were independent predictors of overall survival.CONCLUSION:In patients with cirrhosis and HCC treated with sorafenib,AEs are a common cause of early treatment withdrawal.Vascular invasion and extrahepatic spread condition early response to treatment and survival.Baseline biochemical parameters may be helpful to identify patients at higher risk of shorter overall survival. | Andrea L Inghilesi Donatella Gallori Lorenzo Antonuzzo Paolo Forte Daniela Tomcikova Umberto Arena Stefano Colagrande Silvia Pradella Bernardo Fani Elena Gianni Luca Boni Giacomo Laffi Francesco Di Costanzo Fabio Marra | 2014 | World Journal of Gastroenterology2014，20，3： | 1 |
| 18 | Solid-state interactions, adsorption sites and functionality of Cu-ZnO/ZrO 2 catalysts in the CO 2 hydrogenation to CH 3 OH显示文摘 | Francesco Arena Giuseppe Italiano Katia Barbera Silvia Bordiga Giuseppe Bonura Lorenzo Spadaro Francesco Frusteri | 2008 | Applied Catalysis A, General2008，，1： | 1 |
| 19 | Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation显示文摘AIM:To evaluate the effect of long-term treatment with leukocyte natural-interferon(ln-α-IFN)plus ribavirin(RBV).METHODS:Forty-six patients with hepatitis C virus(HCV)recurrence received 3 MU three times a week of ln-α-IFN plus RBV for 1 mo;then,patients with good tolerability(n=30)were switched to daily IFN administration,while the remaining were treated with the same schedule.Patients have been treated for 12 mo after viral clearance while non-responders(NR)entered in the longterm treatment group.Liver biopsies were planned at baseline,1 year after sustained virological response(SVR)and at 36 mo after start of therapy in NR.MedCalc software package was used for statistical analysis.RESULTS:About 16.7%of genotype 1-4 and 70%of genotype 2-3 patients achieved SVR.Nine patients withdrew therapy because of non-tolerance or noncompliance.A significant improvement in serum biochemistry and histological activity was observed in all SVR patients and long-term treated;100%of patients with SVR achieved a histological response(fibrosis stabilization or improvement)with a significant reduction in mean staging value(from 2.1 to 1.0;P=0.0031);histological response was observed in 84%of long-term treated patients compared to 57%of drop-out.Six patients died during the entire study period(follow-up 40.6±7.7 mo);of them,5 presented with severe HCV recurrence on enrollment.Diabetes(OR=0.38,95%CI:0.08-0.59,P=0.01),leukopenia(OR=0.54,95%CI:0.03-0.57,P=0.03)and severe HCV recurrence(OR=0.51,95%CI:0.25-0.69,P=0.0003)were variables associated to survival.Long-term treatment was well tolerated;no patients developed rejection or autoimmune disease.CONCLUSION:Long-term treatment improves histology in SVR patients and slows disease progression also in NR,leading to a reduction in liver decompensation,graft failure and liver-related death. | Mariarosa Tamè Federica Buonfiglioli Massimo Del Gaudio Andrea Lisotti Paolo Cecinato Antonio Colecchia Francesco Azzaroli Antonietta D’Errico Rosario Arena Claudio Calvanese Chiara Quarneti Giorgio Ballardini Antonio Daniele Pinna Giuseppe Mazzella | 2013 | World Journal of Gastroenterology2013，19，32： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员